(Q79976029)
Statements
Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma (English)
Sandra J Strauss
Frank Morschhauser
Juergen Rech
Roland Repp
Philippe Solal-Celigny
Andreas Engert
Bernard Coiffier
Dieter F Hoelzer
William A Wegener
Nick K W Teoh
David M Goldenberg
T Andrew Lister
24 July 2006